Validation of DREADD agonists and administration route in a murine model of sleep enhancement
Ferrari, Loris L Ogbeide-Latario, Oghomwen E Gompf, Heinrich S Anaclet, Christelle
Citations
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
Chemogenetics is a powerful tool to study the role of specific neuronal populations in physiology and diseases. Of particular interest, in mice, acute and specific activation of parafacial zone (PZ) GABAergic neurons expressing the Designer Receptors Activated by Designer Drugs (DREADD) hM3Dq (PZGABA-hM3Dq) enhances slow-wave-sleep (SWS), and this effect lasts for up to 6 h, allowing prolonged and detailed study of SWS. However, the most widely used DREADDs ligand, clozapine N-oxide (CNO), is metabolized into clozapine which has the potential of inducing non-specific effects. In addition, CNO is usually injected intraperitoneally (IP) in mice, limiting the number and frequency of repeated administration.
Source
Ferrari LL, Ogbeide-Latario OE, Gompf HS, Anaclet C. Validation of DREADD agonists and administration route in a murine model of sleep enhancement. J Neurosci Methods. 2022 Oct 1;380:109679. doi: 10.1016/j.jneumeth.2022.109679. Epub 2022 Jul 30. PMID: 35914577.